Methamphetamine AbuseNCT05700994
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
A study testing Peer Contingency Management in people with Methamphetamine Abuse, run by Oregon Health and Science University at 2 sites in United States.
Trial summary
The main goal of this study is to tests the effect of incentivizing achievement of self-identified, personal harm reduction goals (Contingency management or CM) compared with standard of care (peer harm reduction service with incentives for peer visits) to increase the reach and effectiveness of methamphetamine (MA)… Read more about this study
- Who is it for?
- Ages 18 to 105 years
- Conditions the study is for
- Methamphetamine Abuse
- What is being tested?
- Peer Contingency Management
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,283 participants
- Where
- 2 sitesUnited States
- Study dates
- 13 Nov 2023to 30 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 105 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- This intervention is at the site level. Community-based organization sites are eligible if they:
- Use peer support specialists to provide direct outreach and harm reduction services to people who use drugs
- Are willing to be trained in the two strategies for peer-facilitated contingency management
- Clients who:
- Age 18 and older
- Any stimulant (methamphetamine, cocaine) use in the past 30 days
Show all 9Show fewer
- Willing to accept peer services
- Willing to complete initial and follow-up assessments with peer
- Able to communicate in English or Spanish
Who cannot join
- Community-based organization sites who:
- Do not use peer support specialists to provide direct outreach and harm reduction services to people who use drugs
- Are not willing to be trained in the two strategies for peer-facilitated contingency management
- Clients who:
- Present any danger or threat of violence to peers
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Comagine Health
Portland, Oregon, 97232
Oregon Health & Science University
Portland, Oregon, 97239
About this study
The main goal of this study is to tests the effect of incentivizing achievement of self-identified, personal harm reduction goals (Contingency management or CM) compared with standard of care (peer harm reduction service with incentives for peer visits) to increase the reach and effectiveness of methamphetamine (MA) harm reduction services.
Read the detailed description
Using a hybrid type 1 effectiveness-implementation framework and stepped-wedge design, this study will randomize eighteen community-based peer harm reduction sites to provide contingency management incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals) versus standard of care contingency management (i.e. incentives for peer encounter attendance).
- Conditions
- Methamphetamine Abuse
- Being tested
- Peer Contingency Management, Standard of Care Contingency Management
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peer Contingency ManagementBehavioural
Also called PEER-CM
Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
Standard of Care Contingency ManagementBehavioural
Also called Standard of Care
Participants allocated to standard of care contingency management will receive incentives for peer encounters.
| Study group | Role | What they receive |
|---|---|---|
| PEER-CM | Experimental | Peer-facilitated contingency management (PEER-CM). Receives: Behavioral: Peer Contingency Management |
| Standard of Care | Active comparator | Standard of care contingency management. Receives: Behavioral: Standard of Care Contingency Management |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants who overdose
Test the impact of incentives for achieving self-identified, personal harm reduction goals on the likelihood of overdose among people using methamphetamine at 6 months from enrollment identified through completed assessment.
Measured: 6 months from baseline
Number of participants who achieve self-identified goals
Determine whether incentives for achieving self-identified, personal harm reduction goals increases engagement with harm reduction services at 6 months from enrollment identified through completed assessment.
Measured: 6 months from baseline
Number of participants who engage in substance use disorder treatment
Determine whether incentives for achieving self-identified, personal harm reduction goals increases engagement with treatment services at 6 months from enrollment identified through completed assessment.
Measured: 6 months from baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2023
- Study start13 Nov 2023
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Methamphetamine AbuseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- This is a cluster-randomized pragmatic trial using a hybrid type 1 effectiveness-implementation framework and stepped-wedge design.
- Masking
- None (open label)
- Enrolment
- 1,283 participants (actual)
Sponsor and investigators
- Lead sponsor
- Oregon Health and Science University
- Sponsor type
- University, hospital or other
- Collaborators
- Comagine Health, Oregon Health Authority
- Responsible party
- Principal investigator, P. Todd Korthuis, MD, Oregon Health and Science University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05700994
- Sponsor's protocol ID
- PEER-CM
- Status last verified
- Jan 2026
- First submitted
- 17 Jan 2023
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cooke A, Stack E, Peng L, Cook R, Hartzler B, Leichtling G, Hildebran C, Leahy JM, Payne KS, Kunkel LE, Hoffman K, Korthuis PT. The peers expanding engagement in stimulant harm reduction with contingency management study: a protocol paper. Addict Sci Clin Pract. 2025 Jun 10;20(1):48. doi: 10.1186/s13722-025-00577-8.
PubMed 40495203Peng L, Stack E, Cooke A, Hartzler B, Cook R, Leichtling G, Hildebran C, Leahy J, Payne KS, Kunkel L, Hoffman K, Korthuis PT. Centering peers in design and training for a peer-delivered contingency management program for self-identified harm reduction and treatment goals. Harm Reduct J. 2025 May 6;22(Suppl 1):72. doi: 10.1186/s12954-025-01213-z.
PubMed 40329274
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
- ClinicalTrials.gov ID
- NCT05700994
- Acronym / sponsor ID
- PEER-CM
- Conditions
- Methamphetamine Abuse
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,283 participants (actual)
- Lead sponsor
- Oregon Health and Science UniversityUniversity, hospital or other
- Collaborators
- Comagine Health, Oregon Health Authority
- Study start
- 13 Nov 2023 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 26 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main goal of this study is to tests the effect of incentivizing achievement of self-identified, personal harm reduction goals (Contingency management or CM) compared with standard of care (peer harm reduction service with incentives for peer visits) to increase the reach and effectiveness of methamphetamine (MA) harm reduction services.
Detailed description
Using a hybrid type 1 effectiveness-implementation framework and stepped-wedge design, this study will randomize eighteen community-based peer harm reduction sites to provide contingency management incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals) versus standard of care contingency management (i.e. incentives for peer encounter attendance).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a cluster-randomized pragmatic trial using a hybrid type 1 effectiveness-implementation framework and stepped-wedge design.
| Arm | Type | Receives |
|---|---|---|
| PEER-CM | Experimental | Behavioral: Peer Contingency ManagementPeer-facilitated contingency management (PEER-CM). |
| Standard of Care | Active comparator | Behavioral: Standard of Care Contingency ManagementStandard of care contingency management. |
Who may qualify
- Ages
- 18 to 105 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- This intervention is at the site level. Community-based organization sites are eligible if they:
- Use peer support specialists to provide direct outreach and harm reduction services to people who use drugs
- Are willing to be trained in the two strategies for peer-facilitated contingency management
- Age 18 and older
- Any stimulant (methamphetamine, cocaine) use in the past 30 days
Key exclusion criteria (5 listed)
- Do not use peer support specialists to provide direct outreach and harm reduction services to people who use drugs
- Are not willing to be trained in the two strategies for peer-facilitated contingency management
- Present any danger or threat of violence to peers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peer Contingency ManagementAlso: PEER-CMParticipants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals) | Behavioural | PEER-CM |
| Standard of Care Contingency ManagementAlso: Standard of CareParticipants allocated to standard of care contingency management will receive incentives for peer encounters. | Behavioural | Standard of Care |
Primary outcome
Number of participants who overdose
Time frame: 6 months from baseline
Test the impact of incentives for achieving self-identified, personal harm reduction goals on the likelihood of overdose among people using methamphetamine at 6 months from enrollment identified through completed assessment.
Number of participants who achieve self-identified goals
Time frame: 6 months from baseline
Determine whether incentives for achieving self-identified, personal harm reduction goals increases engagement with harm reduction services at 6 months from enrollment identified through completed assessment.
Number of participants who engage in substance use disorder treatment
Time frame: 6 months from baseline
Determine whether incentives for achieving self-identified, personal harm reduction goals increases engagement with treatment services at 6 months from enrollment identified through completed assessment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Derived from this study: PubMed 40495203Cooke A, Stack E, Peng L, Cook R, Hartzler B, Leichtling G, Hildebran C, Leahy JM, Payne KS, Kunkel LE, Hoffman K, Korthuis PT. The peers expanding engagement in stimulant harm reduction with contingency management study: a protocol paper. Addict Sci Clin Pract. 2025 Jun 10;20(1):48. doi: 10.1186/s13722-025-00577-8.
- Derived from this study: PubMed 40329274Peng L, Stack E, Cooke A, Hartzler B, Cook R, Leichtling G, Hildebran C, Leahy J, Payne KS, Kunkel L, Hoffman K, Korthuis PT. Centering peers in design and training for a peer-delivered contingency management program for self-identified harm reduction and treatment goals. Harm Reduct J. 2025 May 6;22(Suppl 1):72. doi: 10.1186/s12954-025-01213-z.
- Individual participant dataSharing planned: No
Related trials for Methamphetamine Abuse
RecruitingPhase 2
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
Methamphetamine Intoxication, Methamphetamine Disorders
Recruiting
rTMS for Craving in Methamphetamine Use Disorder
Methamphetamine Abuse, Substance Use Disorders
RecruitingObservational study
Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use
Methamphetamine Induced Psychosis, Cannabis Use
Active, not recruitingPhase 3
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
Methamphetamine-dependence, Methamphetamine Abuse
RecruitingPhase 2
Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder
Methamphetamine Abuse, Methamphetamine-dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Peer Contingency Management in people with Methamphetamine Abuse, run by Oregon Health and Science University at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants who overdose (time frame: 6 months from baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05700994, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026; AzTrials last refreshed its copy on 30 Oct 2026.